摘要
目的采用层次分析法(AHP)加权的TOPSIS法评价沙库巴曲缬沙坦治疗慢性心力衰竭的用药合理性。方法以沙库巴曲缬沙坦药品说明书、诊疗指南、专家共识及相关文献为依据,建立沙库巴曲缬沙坦治疗慢性心力衰竭的合理用药评价标准,采用AHP法对指标进行赋权,并结合TOPSIS法对本院2022年1月─2022年6月使用沙库巴曲缬沙坦治疗慢性心力衰竭的病历进行合理性评价。结果建立的评价标准权重较高的前5个指标分别为适应证0.2778、禁止联用0.1996、联合治疗0.1763、给药剂量0.1140、药品转换0.0815。共纳入90份病历,其中评价为合理用药22例(24%),基本合理用药50例(56%),不合理用药18例(20%)。结论AHP加权的TOPSIS法可用于沙库巴曲缬沙坦治疗慢性心力衰竭的合理性评价,能发现临床应用存在的问题,为临床药师进行药学干预提供依据,促进临床科室合理用药。
AIM To analytical hierarchy process(AHP)and technique for order preference by similarity to an ideal solution(TOPSIS)were used to evaluate the rationality of the use of sacubitril valsartan in the treatment of chronic heart failure,to provide a reference for clinical pharmacists to intervene and promote the rational use of clinical drugs.METHODS Based on the drug instruction of sacubitril valsartan,treatment guidelines,expert consensus and relevant literature,the evaluation criteria for the rational use of sacubitril valsartan in the treatment of chronic heart failure was established,and the AHP method was used to assign weights to the indicators and the TOPSIS method was used to evaluate the rational use of sacubitril valsartan in the treatment of chronic heart failure in our hospital records from January 2022 to June 2022.RESULTS The top 5 indicators with higher weight of the established evaluation criteria were 0.2778 for indications,0.1996 for prohibited combination,0.1763 for combination therapy,0.1140 for dose administration and 0.0815 for drug conversion.Ninety medical records were included,of which 22 cases(24%)were evaluated as reasonable medication use,50 cases(56%)as basic reasonable medication use and 18 cases(20%)as unreasonable medication use.CONCLUSION The AHP-weighted TOPSIS method can be used to evaluate the rationality of sacubitril valsartan in the treatment of chronic heart failure,which can identify problems in clinical application,provide a basis for pharmacological intervention by clinical pharmacists and promote rational drug use in clinical departments.
作者
李小东
任心慈
孙伟
王广川
桑翩翩
王芳
钱文
王静
LI Xiao-dong;REN Xin-ci;SUN Wei;WANG Guang-chuan;SANG Pian-pian;WANG Fang;QIAN Wen;WANG Jing(Department of Pharmacy,Huaibei People’s Hospital Attached to Bengbu Medical University/Huaibei People’s Hospital,Huaibei ANHUI 235000,China;Department of Medical,Huaibei People’s Hospital Attached to Bengbu Medical University/Huaibei People’s Hospital,Huaibei ANHUI 235000,China;Department of Cardiology,Huaibei People’s Hospital Attached to Bengbu Medical University/Huaibei People’s Hospital,Huaibei ANHUI 235000,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2024年第9期704-710,共7页
Chinese Journal of New Drugs and Clinical Remedies
基金
淮北市科技计划项目(2022HK010)。
作者简介
李小东,男,主任药师,学士,主要从事药事管理和医院药学工作,E-mail:ahhblxd@163.com。
